Pharma Supplier: High Court Should Deny Cert In FCA, Anti-Kickback Violations Row
WASHINGTON, D.C. — A pharmaceutical wholesaler and related entities argue in their Aug. 16 U.S. Supreme Court brief that the court should not grant certiorari to review the Second Circuit U.S....To view the full article, register now.
Already a subscriber? Click here to view full article